role of upfront surgery and its integration with multimodal therapies, penile cancer, loco-regional metastases, pelvic lymph nodes, inguinal LN dissection, patients with cN+ resectable disease, predictors of recurrence-free survival.
Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound,…
Alicia Morgans engages in a discussion with Benjamin Lowentritt, focusing on comprehensive care for prostate cancer patients, particularly those with de novo metastatic hormone-sensitive disease.…
Ashish Kamat hosts Sima Porten and Roger Li to discuss the management of BCG-unresponsive bladder cancer. They emphasize personalized patient care, starting by understanding patients’…
Zach Klaassen speaks with Todd Morgan about innovative approaches in the management of prostate cancer post-prostatectomy. Dr. Morgan presents compelling new data on the prostate…
Christopher Pieczonka discusses the management of metastatic hormone-sensitive prostate cancer with a focus on triple therapy. Dr. Pieczonka emphasizes that androgen deprivation therapy (ADT) is…
Zach Klaassen converses with Daniel Saltzstein about the collaborative approach in treating metastatic hormone-sensitive prostate cancer with triplet therapy. Dr. Saltzstein describes their unique setup…
Alicia Morgans hosts a discussion with Damian Sorce, a urologist, and Manoj Bupathi, a medical oncologist, on their collaboration in treating patients with metastatic hormone-sensitive…
Sam Chang interviews Karim Chamie about pivotal clinical trials in urothelial carcinoma presented at AUA 2024. Dr. Chamie discusses the MoonRISe-1 trial, a Phase III…
Mark Tyson presents results from the BOND-003 study, evaluating the efficacy of cretostimogene grenadenorepvec monotherapy in treating BCG-unresponsive non-muscle-invasive bladder cancer. Cretostimogene, an oncolytic adenovirus,…
Zach Klaassen engages in a discussion with Vahan Kassabian about the evolving landscape of nonmetastatic castration-resistant prostate cancer (nmCRPC) management. They delve into how novel…
